Trial Information
Plus Therapeutics is evaluating REYOBIQ™ (rhenium Re186 obisbemeda), a novel radiotherapy for patients with Leptomeningeal Metastases.
Watch now to learn more.
Patient Eligibility
Only a qualified healthcare professional can determine whether or not you are eligible to participate in a clinical trial. However, this information may be beneficial in initiating a conversation with your physician. Full patient eligibility will be discussed upon patient screening.
Age Range
Adults, 18 years and older
Condition
Leptomeningeal Metastases from any solid tumor cancers (i.e. breast, lung, melanoma, gastrointestinal)
Prior Treatment
No prior whole brain or spinal cord radiation therapy
Informed Consent
Able to understand the study purposes and risks
Gender
All; Women have negative pregnancy test at screening; Subjects must use effective contraception during study
Principal Investigators
There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.
Andrew Brenner, M.D., Ph.D.
UT Health San Antonio, Mays Cancer Center
San Antonio, Texas
Previously Enrolled
as part of the ReSPECT-LM single-dose clinical trial:
Michael Youssef, M.D.
UT Southwestern Medical Center
Priya Kumthekar, M.D.
Northwestern Memorial Hospital
Michael Schulder, M.D.
North Shore University Hospital
Pierre Giglio, M.D.
The Ohio State University Cancer Center
Randy S. D’Amico, M.D.
Lenox Hill Hospital
Trial Locations
Please visit this website regularly for updates as new locations are added.
UT Health Science Center
San Antonio
Previously Enrolled
as part of the ReSPECT-LM single-dose clinical trial:
UT Southwestern Medical Center – Dallas
Northwestern Memorial Hospital – Chicago
North Shore University Hospital – New York
Ohio State University – Columbus
Lenox Hill Hospital – New York
What Can You Do Next?
Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.
Discuss With Your Physician
Anyone participating in a clinical trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your physician first.
Print, save, or email this page to your physician to discuss at your next visit
Contact A Trial Coordinator
A trial coordinator is a specialized researcher who supports the management and coordination of clinical research studies. If you are interested in participating in a clinical trial, you may call a trial coordinator directly at one of the trial locations below.
UT Health Science Center
San Antonio
Leticia Velten
210-450-1921
velten@uthscsa.edu
Contact Us
Request More Information
News
August 13, 2024
August 12, 2024
July 25, 2024
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference
July 2, 2024
June 7, 2024
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
May 9, 2024
Publications
Posters
Presentations
Phase 1 Dose Escalation of Rhenium (186Re) Obisbemeda (Rhenium Nanoliposome, 186RNL) for the Treatment of Leptomeningeal Metastases (LM), SNO/ASCO CNS Metastases Conference Oral Presentation, August 8, 2024
Emerging Novel Diagnostic and Therapeutic Approaches for Leptomeningeal Metastases, SNO/ASCO CNS Metastases Independent Symposium, August 8, 2024
Targeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the ReSPECT Phase 1/2 Trials, Gordon Research Conference, July 8, 2024
Phase 1A of the ReSPECT-LM Trial: Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases (LM), Cancer Prevention & Research Institute of Texas (CPRIT) Innovations Conference, October 3, 2023
KOL Roundtable on Leptomeningeal Metastases: An Obvious Disease Target for Radiotherapeutic Intervention, SNO/ASCO CNS Cancer Conference, August 11, 2023
Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1/2a Trial, EANM Congress, October 19, 2022
Resources
Note: all external links
- American Brain Tumor Association
- American Cancer Society
- Brain Tumor Network
- Dictionary of Cancer Terms
- End Brain Cancer Initiative
- MedlinePlus (NIH)
- National Brain Tumor Society
- National Cancer Institute
- National Comprehensive Cancer Network
- Support Groups Listing
- The Brain Tumour Charity
- Trial Connect
- VirtualTrials.com
- Voices Against Brain Cancer
Updates
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care At Plus Therapeutics, our mission is clear: to address some of the toughest challenges in oncology by improving the efficacy, precision, and convenience of modern radiotherapeutic treatments....
June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches
June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches Following Brain Cancer Awareness Month, June marks Brain and Spine Metastasis Awareness Month, a critical time to raise awareness about the...
Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast
Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast In case you missed it, Plus Therapeutics President and CEO Dr. Marc Hedrick recently joined Ayesha Rashid on the Xtalks Life Sciences Podcast to discuss the company’s...
NMN Symposium 2025
New Data on REYOBIQ™ for Leptomeningeal Metastases Presented at the NMN Conference! Plus Therapeutics is pleased to announce that new clinical data on its lead investigational therapy, REYOBIQ™ (rhenium Re 186 obisbemeda), was presented at the Nuclear Medicine and...
Contents
- 1 You Deserve Every Option.
- 2 See if You Qualify for our Leptomeningeal Metastases Clinical Trial
- 2.1 Trial Information
- 2.2 Patient Eligibility
- 2.3 Principal Investigators
- 2.4 Trial Locations
- 2.5 What Can You Do Next?
- 2.6 Contact A Trial Coordinator
- 2.7 Contact Us
- 2.8 Request More Information
- 2.9 News
- 2.10 Publications
- 2.11 Resources
- 2.12 Updates
- 2.13 Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care
- 2.14 June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches
- 2.15 Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast
- 2.16 NMN Symposium 2025
- 2.17